The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS
Introduction EXO-CD24 are exosomes genetically manipulated to over-express Cluster of Differentiation (CD) 24. It consists of two breakthrough technologies: CD24, the drug, as a novel immunomodulator that is smarter than steroids without any side effects, and exosomes as the ideal natural drug carrier. Methods A randomized, single blind, dose-finding phase IIb trial in hospitalized patients with mild to moderate Coronavirus disease 2019 (COVID-19) related Acute Respiratory Distress Syndrome (ARDS) was carried out in two medical centers in Athens. Patients received either $ 10^{9} $ or $ 10^{10} $ exosome particles of EXO-CD24, daily, for five consecutive days and monitored for 28 days. Efficacy was assessed at day 7 among 91 patients who underwent randomization. The outcome was also compared in a post-hoc analysis with an income control group (n = 202) that fit the inclusion and exclusion criteria. Results The mean age was 49.4 (± 13.2) years and 74.4% were male. By day 7, 83.7% showed improved respiratory signs and 64% had better oxygen saturation ($ SpO_{2} $) (p < 0.05). There were significant reductions in all inflammatory markers, most notably in C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, fibrinogen and an array of cytokines. Conversely, levels of the anti-inflammatory cytokine Interleukin-10 (IL-10) were increased (p < 0.05). Of all the documented adverse events, none were considered treatment related. No drug-drug interactions were noted. Two patients succumbed to COVID-19. Post-hoc analysis revealed that EXO-CD24 patients exhibited greater improvements in clinical and laboratory outcomes compared to an observational income control group. Conclusions EXO-CD24 presents a promising therapeutic approach for hyper-inflammatory state and in particular ARDS. Its unique combination of exosomes, as a drug carrier, and CD24, as an immunomodulator, coupled with inhalation administration, warrants further investigation in a larger, international, randomized, quadri-blind trial against a placebo..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Respiratory research - 25(2024), 1 vom: 01. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grigoropoulos, Ioannis [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12931-024-02759-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055374352 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055374352 | ||
| 003 | DE-627 | ||
| 005 | 20240402064724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240402s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-024-02759-5 |2 doi | |
| 035 | |a (DE-627)SPR055374352 | ||
| 035 | |a (SPR)s12931-024-02759-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Grigoropoulos, Ioannis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Introduction EXO-CD24 are exosomes genetically manipulated to over-express Cluster of Differentiation (CD) 24. It consists of two breakthrough technologies: CD24, the drug, as a novel immunomodulator that is smarter than steroids without any side effects, and exosomes as the ideal natural drug carrier. Methods A randomized, single blind, dose-finding phase IIb trial in hospitalized patients with mild to moderate Coronavirus disease 2019 (COVID-19) related Acute Respiratory Distress Syndrome (ARDS) was carried out in two medical centers in Athens. Patients received either $ 10^{9} $ or $ 10^{10} $ exosome particles of EXO-CD24, daily, for five consecutive days and monitored for 28 days. Efficacy was assessed at day 7 among 91 patients who underwent randomization. The outcome was also compared in a post-hoc analysis with an income control group (n = 202) that fit the inclusion and exclusion criteria. Results The mean age was 49.4 (± 13.2) years and 74.4% were male. By day 7, 83.7% showed improved respiratory signs and 64% had better oxygen saturation ($ SpO_{2} $) (p < 0.05). There were significant reductions in all inflammatory markers, most notably in C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, fibrinogen and an array of cytokines. Conversely, levels of the anti-inflammatory cytokine Interleukin-10 (IL-10) were increased (p < 0.05). Of all the documented adverse events, none were considered treatment related. No drug-drug interactions were noted. Two patients succumbed to COVID-19. Post-hoc analysis revealed that EXO-CD24 patients exhibited greater improvements in clinical and laboratory outcomes compared to an observational income control group. Conclusions EXO-CD24 presents a promising therapeutic approach for hyper-inflammatory state and in particular ARDS. Its unique combination of exosomes, as a drug carrier, and CD24, as an immunomodulator, coupled with inhalation administration, warrants further investigation in a larger, international, randomized, quadri-blind trial against a placebo. | ||
| 650 | 4 | |a ARDS exosomes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CD24 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a EXO-CD24 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Covid-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Phase IIb |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Tsioulos, Georgios |4 aut | |
| 700 | 1 | |a Kastrissianakis, Artemis |4 aut | |
| 700 | 1 | |a Shapira, Shiran |4 aut | |
| 700 | 1 | |a Green, Orr |4 aut | |
| 700 | 1 | |a Rapti, Vasiliki |4 aut | |
| 700 | 1 | |a Tsakona, Maria |4 aut | |
| 700 | 1 | |a Konstantinos, Thomas |4 aut | |
| 700 | 1 | |a Savva, Athina |4 aut | |
| 700 | 1 | |a Kavatha, Dimitra |4 aut | |
| 700 | 1 | |a Boumpas, Dimitrios |4 aut | |
| 700 | 1 | |a Syrigos, Konstantinos |4 aut | |
| 700 | 1 | |a Xynogalas, Ioannis |4 aut | |
| 700 | 1 | |a Leontis, Konstantinos |4 aut | |
| 700 | 1 | |a Ntousopoulos, Vasileios |4 aut | |
| 700 | 1 | |a Sakka, Vissaria |4 aut | |
| 700 | 1 | |a Sardelis, Zafeiris |4 aut | |
| 700 | 1 | |a Fotiadis, Andreas |4 aut | |
| 700 | 1 | |a Vlassi, Lamprini |4 aut | |
| 700 | 1 | |a Kontogianni, Chrysoula |4 aut | |
| 700 | 1 | |a Levounets, Anastasia |4 aut | |
| 700 | 1 | |a Poulakou, Garyfalia |4 aut | |
| 700 | 1 | |a Gaga, Mina |4 aut | |
| 700 | 1 | |a MacLoughlin, Ronan |4 aut | |
| 700 | 1 | |a Stebbing, Justin |4 aut | |
| 700 | 1 | |a Arber, Nadir |4 aut | |
| 700 | 1 | |a Antoniadou, Anastasia |4 aut | |
| 700 | 1 | |a Tsiodras, Sotirios |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d BioMed Central, 2001 |g 25(2024), 1 vom: 01. Apr. |w (DE-627)SPR028499905 |w (DE-600)2041675-1 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:01 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12931-024-02759-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 01 |c 04 | ||